Tomas Ganz is a Distinguished Professor of Medicine and Pathology at the David Geffen School of Medicine at University of California, Los Angeles (UCLA). His research focus is on the biological role of peptide mediators in innate immunity and iron metabolism. He investigated the pathogenesis of anemia of inflammation and iron overload states, and discovered and characterized hepcidin and erythroferrone, the principal hormones of iron homeostasis. He has helped start three biotechnology enterprises, Intrinsic LifeSciences, Merganser Biotech, and Silarus Therapeutics, focused on the diagnostic and therapeutic applications of hepcidin and erythroferrone. Tomas has also been a scientific advisor to the leading pharmaceutical and biotechnology companies.